Drug intelligence / Profile preview

PVS-502

Development stage: Preclinical
Lead developer: Takeda
Modality: Cell Therapies

Overview

PVS-502 is an endothelial cell therapy initially developed by Pervasis Therapeutics and later acquired by Shire. It was in preclinical development for the maintenance of vascular access in patients undergoing hemodialysis. This therapy is based on a novel cell-based platform intended to address unmet needs in vascular healing.

Beyond the preview

Go deeper on PVS-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVS-502.

Explore the full profile